ESMO 2025: A Phase III Study of Capivasertib + Abiraterone versus Placebo + Abiraterone in Patients with PTEN-deficient De Novo Metastatic Hormone-sensitive Prostate Cancer (mHSPC): CAPItello-281 – UroToday

Written by

admin

in

  1. ESMO 2025: A Phase III Study of Capivasertib + Abiraterone versus Placebo + Abiraterone in Patients with PTEN-deficient De Novo Metastatic Hormone-sensitive Prostate Cancer (mHSPC): CAPItello-281  UroToday
  2. Truqap Extends Radiographic Progression-Free Survival in Some With Prostate Cancer  CUREtoday.com
  3. Capivasertib prolongs rPFS in PTEN-deficient hormone-sensitive prostate cancer  Urology Times

Continue Reading

More posts